Medicus Pharma (NASDAQ:MDCX) announced that the United Arab Emirates Department of Health – Abu Dhabi (DOH) has granted Investigational New Drug (IND) authorization for its Phase 2a PRECISION-E2 clinical study evaluating Teverelix in women with moderate-to-severe symptomatic endometriosis.
The authorization follows the DOH's review of the company's chemistry, manufacturing and controls, non-clinical, clinical and safety documentation. The study has been approved to proceed, subject to site-specific institutional review board and ethics approvals.
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported imaging results from the third patient with multiple system atrophy (MSA) to complete dosing in its ongoing Phase 2 clinical trial of intranasal foralumab, with PET scans showing reductions in brain inflammation following treatment.
The company said quantitative analysis of PET imaging demonstrated reductions in inflammatory activity in brain regions commonly affected by MSA, including the basal ganglia and cerebellar white matter.
Namibia Critical Metals (TSX-V:NMI, OTCQB:NMREF) announced that Japan Organization for Metals and Energy Security (JOGMEC) and Toyota Tsusho Corporation have established TJ Namibia Rare Earths Corporation (TJNREC), a jointly owned special purpose company that will hold Japan's 50% participating interest in the Lofdal Heavy Rare Earth Project in Namibia.
The company said the formation of TJNREC coincides with the completion of Japan's previously announced C$23 million earn-in commitment under the joint venture agreement.
Futura Medical PLC (AIM:FUM, OTC:FAMDF, FRA:GYX) said its stronger Eroxon Intense erectile dysfunction gel has been cleared for launch across the European Economic Area and UK, widening the group’s flagship consumer-health franchise.
The clearance follows the completion of design, validation and pre-market regulatory work under Futura’s existing European CE certification and UKCA approval. Commercial partner Cooper Consumer Health can now launch the formulation across its licensed territories.
Provaris Energy Ltd (ASX:PV1, OTC:GBBLF, FRA:WS90) made further technical and commercial progress across its compressed hydrogen and liquid carbon dioxide storage technologies during the June 2026 quarter, completing a major engineering milestone and broadening the potential market for its large-scale LCO₂ tank design.
The company completed the structural engineering package for its proprietary 25,000-cubic-metre LCO₂ tank on schedule and within budget, submitting the design to maritime classification society DNV for review.
American Rare Earths Ltd (ASX:ARR, OTCQX:ARRNF) accelerated development of its flagship Halleck Creek Rare Earths Project during the June 2026 quarter, advancing feasibility drilling, pilot-scale processing and preparations for a planned NASDAQ listing.
The company ended the quarter with A$18.5 million in cash after increasing investment across drilling, technical studies, pilot plant development and broader project planning.
archTIS Ltd (ASX:AR9, OTCQB:ARHLF) closed the June 2026 quarter with annual recurring revenue of $14.8 million, record full-year contracted sales and growing momentum across major defence programs in the United States and Australia.
The data security specialist reported fourth-quarter revenue of $3.5 million, up 92% on the prior corresponding period, while ARR increased 209% year-on-year across a diversified base of 225 customers.
St George Mining Ltd (ASX:SGQ, FRA:S0G, OTC:SGQMF) advanced the Araxá Niobium-Rare Earths Project during the June 2026 quarter, delivering encouraging metallurgical results, thick high-grade drill intersections and the appointment of Worley as feasibility technical adviser.
The company also strengthened its balance sheet through a A$60 million institutional-led capital raising, ending the quarter with A$80.7 million in cash and reporting a cash balance of about A$98 million following completion of the second placement tranche after quarter-end.
Noble Helium Ltd (ASX:NHE, OTC:NBHEF, FRA:GN1) accelerated preparations for its Kinambo helium drilling campaign during the June 2026 quarter after raising A$12 million, converting A$6.6 million of debt into equity and securing a rig for the North Rukwa Project in Tanzania.
The company ended the quarter with A$6.69 million in cash and is preparing for the Schramm T130 XD rig to mobilise in August 2026, following site preparation and optimisation of the first two Kinambo wells.
Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) advanced preparations to return its lead cancer drug HMBD-002 to the clinic during the June 2026 quarter, completing manufacture of a new drug substance batch, raising $2.2 million and presenting supporting data at two major international oncology conferences.
The biotechnology company expects the newly manufactured material to be filled into vials and released for use in a new clinical trial in September 2026, supporting its plan to restart clinical development during the second half of the year.
Lindian Resources Ltd (ASX:LIN, OTC:LINIF) moved closer to becoming a rare earths producer during the June 2026 quarter, completing key construction and mining-readiness milestones at the Kangankunde Rare Earths Project in Malawi while strengthening its balance sheet and advancing a downstream processing strategy in Kazakhstan.
The company maintained its target for first concentrate production in the fourth quarter of 2026, with front-end commissioning scheduled for October and practical completion targeted for mid-November.
Altech Batteries Ltd (ASX:ATC, OTC:ALTHF, FRA:A3Y) used the June 2026 quarter to concentrate its resources on commercialising the CERENERGY® sodium-chloride solid-state battery project, securing an extension to a conditional €46.7 million German Government grant while discontinuing its Silumina Anodes™ development program.
The German Federal Ministry for Economic Affairs and Energy extended the deadline for Altech to achieve full financial close for CERENERGY from June 30 to September 30, 2026.